Astellas, Seattle Genetics get FDA’s accelerated approval for bladder cancer drug Padcev

This article was originally published here

Padcev, a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4 protein, has secured approval under the FDA’s Accelerated Approval Program based on tumour response rate. Nectin-4, which

The post Astellas, Seattle Genetics get FDA’s accelerated approval for bladder cancer drug Padcev appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply